We would love to hear your thoughts about our site and services, please take our survey here.
10:1 ratio for US holders of the stock.
20:1 ratio so 975 for 19,000.
Denny, I picked up the peer review from another chap on the Telegram group.
The correspondence with the company was mine and I think it looks positive moving forward.
We’ve had our differences here but I feel for you guys who have been burnt in SNG and ODX. I certainly didn’t see the SNG fall coming, the SP had looked rock solid there for quite a while when everything else was tumbling.
All being well, hopefully you guys can have some joy here with Accustem and TLSA.
Suffering some heavy losses here myself and certainly not out of the woods yet but still a believer in both companies.
Jimmy, I can see why people are frustrated here. Comms have been poor and people have lost money in the meantime.
It would be nice to see both companies rise like a phoenix from the flames.
An update following a phone call with Hana in the Tiziana office:
She is very aware that comms have not been very good and she is also aware of the negativity around the social media account.
She has fed this to those above and they are very aware.
It will get better going forward.
My point to her being that this has affected the share price as it seems new investors are not being attracted and existing investors are also not being enticed to invest more, it’s a domino effect.
She confirmed that she is a busy lady dealing with questions from frustrated investors.
I made the point that it isn’t fair her taking the flak on the frontline, there needs to come a time for the two guys at the top to front up.
Accustem…always hard to get her to commit on timelines.
Originally I spoke to her and she told me we could expect something before Christmas.
On this occasion she was non-commital at first so I prodded a bit more and said can I have a timeline roughly, 2-4 weeks to hear news and she said yes.
So I don’t think news is that far away.
We’ve come this far!
She also said it’s been a very busy year and a lot of progress has been made in the background.
Ha, they are definitely wrong there! If they are adamant, speak to Hana at Tiziana and she will be able to provide a document showing the record dates to them. It is also available in the RNS’s on this page.
Just posted it on the TILS page Bluebelly.
https://www.sciencedirect.com/science/article/pii/S0959804922000077
Sang, check out today’s peer review of StemprintER in comparison to OncotypeDX.
I agree that you are right to knock TILS progress on trials but don’t write it off completely, there has obviously been a lot going on in the background.
You may find that some money finds it’s way from TLSA into 4D if it rises first.
Good luck to all here, it’s been a tough time for investors in this sector.
Chelly, 30th October 2020 was the record date for UK holders.
Different dates for US holders.
Cheers OldApache. I got the wrong end of the stick there, I thought you were with HL.
Yes, my Lloyds/Halifax have also been consolidated and tradeable for weeks.
I’ve no intention of selling at these levels but it’s just frustrating to have been locked out through HL, especially for this prolonged period.
Hi Old Apache, when did this share consolidation take place for yourself with HL?
I’m still waiting for mine to occur.
I was expecting the HL system to consolidate shareholders at the same time, which it seems has happened with other brokers.
Sang, as you know, the distressed seller coupled with market sentiment is pulling the price down over at 4D.
There is obviously a decent value attributed to anti CD3 mabs, just look at the valuation of PRVB which seems a lofty valuation. It has also recovered well this week along with other Nasdaq bio stocks.
If it does happen and TLSA eventually get some of these proposed Phase 2 trials out of the starting blocks I’m sure we will see the SP move through the gears nicely.
Add in some positive Accustem news and this could suddenly look like a decent investment.
Volume is rubbish. News is badly needed to raise the interest levels of investors here. A new wave of investors is needed. It seems existing investors are either maxed out or fed up so probably barely topping up now.
There was also no SEC filing in regards of the decision to take the route of using Foralumab as a treatment for Type 1 diabetes, administered subcutaneously.
In the old days of TILS, this kind of information was RNS’d for fun.
Interesting to see that the FDA have given ProventionBio another chance. Stock rose 30% on news.
TLSA are also following the diabetes route now.
https://www.nasdaq.com/articles/why-provention-bio-stock-skyrocketed-today?amp
Bo, the BioPharma sector has been down across the board. Logic says that will turn at some point.
We are all in charge of our own investment decisions ultimately.
No point trying to bait a guy who does some good research behind the scenes on behalf of investors.
He or others can’t control news flow from the company and on that point, I do agree with you. Some of the comms and the handling of the Accustem demerger haven’t been great.
Just under a year ago, (early Feb) the SP was sitting pretty and most people had a chance to exit then with a decent profit.
Only ourselves to blame, I still kick myself for not selling TILS when it went to nearly £3.
Loyalty aside, that should have been an obvious sell which I missed.
If you look across most chat boards at the moment, there are loads of people who have been wounded by the downturn in the markets.
Some are trapped in stocks which are unlikely to turn.
At least we are cashed up here and there are positive signs ahead in the pipeline.
We also have Accustem for a lot of us! Or maybe I shouldn’t have mentioned the A word haha!
Surfer, the amount of shares you hold has been halved due to the 2:1 ADR conversion.
The value would have been the same (or very similar considering two markets) if your shares were still UK listed.
It will turn.
15% down at one point, 15% up at another point.
Finished 2.73% up after another dip before that!